<- Go Home
MedinCell S.A.
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Market Cap
EUR 910.1M
Volume
84.0K
Cash and Equivalents
EUR 59.0M
EBITDA
-EUR 10.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 27.7M
Profit Margin
100.00%
52 Week High
EUR 39.68
52 Week Low
EUR 12.00
Dividend
N/A
Price / Book Value
-55.56
Price / Earnings
-44.20
Price / Tangible Book Value
-47.82
Enterprise Value
EUR 905.5M
Enterprise Value / EBITDA
-96.53
Operating Income
-EUR 10.8M
Return on Equity
64.48%
Return on Assets
-10.56
Cash and Short Term Investments
EUR 71.9M
Debt
EUR 67.3M
Equity
-EUR 16.4M
Revenue
EUR 27.7M
Unlevered FCF
EUR 7.9M
Sector
Pharmaceuticals
Category
N/A